Together with survivin being under the control of p53 in glioma stem cells, our results suggest that the inhibition of MDM2 is a good approach to eliminating glioma stem cells because it simultaneously targets two layers of their vulnerability. This evidence concerns the gene BIRC5 and central nervous system cancer.